Sarepta Therapeutics, Inc.
Moat Score — Sarepta Therapeutics, Inc.
Total Moat Score
15 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 4 / 5 | Sarepta holds the first and, in several cases, only approved therapies for specific DMD exon-skip mutations (EXONDYS 51, VYONDYS 53, AMONDYS 45) plus ELEVIDYS, the first approved DMD gene therapy, representing a deep and largely uncontested patent and regulatory-exclusivity estate in Duchenne muscular dystrophy. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | As a specialty biopharmaceutical company serving a narrow rare-disease population, Sarepta has no low-cost manufacturing or distribution advantage over other rare-disease drugmakers. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 4 / 5 | Orphan-drug status and the absence of direct generic or branded competitors for its specific exon-skip and gene-therapy products support strong list pricing, though the November 2025 ELEVIDYS boxed warning creates real downside risk to continued pricing and volume. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | Sarepta's rare-disease therapies carry no network effect — one patient's treatment does not increase the value of the therapy for another patient. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 3 / 5 | DMD patients and treatment centers that have already selected a specific exon-skipping or gene therapy face real clinical switching costs, though the 2025 ELEVIDYS safety crisis illustrates that a sufficiently serious safety signal can itself force patients and physicians to reconsider treatment. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 3 / 5 | The DMD patient population is small enough, and the specialized manufacturing and clinical infrastructure required is complex enough, that Sarepta's existing commercial scale is a real barrier to a new entrant targeting the same narrow mutation-specific populations. |